APLM Apollomics Inc

-0.195 (-4.95%)
Sep 29 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 10,993
Bid Price 3.44
Ask Price 3.97
News -
Day High 3.99


52 Week Range


Day Low 3.71
Company Name Stock Ticker Symbol Market Type
Apollomics Inc APLM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.195 -4.95% 3.745 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.98 3.71 3.99 3.745 3.94
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
102 10,993 $ 3.85 $ 42,291 - 3.48 - 49.00
Last Trade Time Type Quantity Stock Price Currency
16:10:53 priorref 357 $ 3.745 USD

Apollomics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
325.05M 86.80M - 1.45M -240.81M -2.77 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Apollomics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No APLM Message Board. Create One! See More Posts on APLM Message Board See More Message Board Posts

Historical APLM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.484.063.483.797,1880.2657.61%
1 Month4.8154.8153.484.018,115-1.07-22.22%
3 Months5.356.203.485.1313,148-1.61-30.0%
6 Months18.6049.003.489.69101,189-14.86-79.87%
1 Year18.6049.003.489.69101,189-14.86-79.87%
3 Years18.6049.003.489.69101,189-14.86-79.87%
5 Years18.6049.003.489.69101,189-14.86-79.87%

Apollomics Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now